Status:
COMPLETED
Effectiveness and Safety of Firmagon®
Lead Sponsor:
Ferring Pharmaceuticals
Collaborating Sponsors:
Ferring Arzneimittel GmbH
Conditions:
Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
Eligibility:
MALE
18+ years
Brief Summary
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® t...
Eligibility Criteria
Inclusion
- therapeutic need according to SPC
- written informed consent
Exclusion
- \- contraindications according to SPC
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
676 Patients enrolled
Trial Details
Trial ID
NCT00930319
Start Date
June 1 2009
End Date
December 1 2013
Last Update
November 9 2023
Active Locations (230)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site, Heinrich-Rieger-Str. 15
Aalen, Germany
2
Investigational Site, Weidenfelder Straße 1
Aalen, Germany
3
Investigational Site
Abensberg, Germany
4
Investigational Site
Ahaus, Germany